Building a More Responsive Medical Countermeasure Capability through Technological Innovation

Biomedical Advanced Research and Development Authority (BARDA)

Jonathan Seals
Director, Strategic Science and Technology
HHS/ASPR/BARDA
BARDA’s Mission

• To provide medical countermeasures that address public health and medical consequences of chemical, biological, radiological, and nuclear accidents and attacks, pandemic influenza, and emerging infectious diseases

• Product licensure
• Countermeasure stockpiling
• Manufacturing capacity
• Effective delivery
• Development infrastructure
• Technical innovations
The Preparedness Challenge

- Large number of threats, diverse types
- Wide array of countermeasures needed
- Possibility of new, unanticipated threats
- Need for rapid response and delivery

- Medical countermeasure enterprise well established for commercial products
- Can the current enterprise be used or adapted to serve the purpose of public health threat preparedness and response?
Gaps in the Enterprise for Public Health Emergency Preparedness

• The current enterprise did not evolve for the purpose of emergency preparedness and response
• Limited or no commercial market for many threats
• Enterprise evolved for safety and efficacy, not speed and cost

• Preparing for and responding to the threats that fall under BARDA’s mandate will strain its capabilities
  — Secretary’s Countermeasure Review
  — PCAST report
Adapting the Current Enterprise through Technological Innovation

• New technologies, tools, approaches, and capabilities will help adapt the current enterprise to operate according to a more “responsive” paradigm

• BARDA is actively working to advance elements that will make this shift possible

• BARDA’s Strategic Science and Technology Division is a focal point for ideas that will provide the solutions needed
  • Scouting
  • Strategic vision
  • BARDA’s Innovations program provides support for advancing and evaluating programs that offer new capabilities
Innovation is a Key Part of BARDA’s Mandate*

• “shall develop and make public a strategic plan to integrate biodefense and emerging infectious disease requirements with the advanced research and development, strategic initiatives for innovation, and the procurement of qualified countermeasures and qualified pandemic or epidemic products”

• “…shall guide…innovation in technologies that may assist advanced research and development of qualified countermeasures and qualified pandemic or epidemic products”

• “…shall coordinate the acceleration of countermeasure and product advanced research and development by…promoting innovation to reduce the time and cost of countermeasure and product advanced research and development”

• “SUPPORTING INNOVATION- …may award contracts, grants, and cooperative agreements, or enter into other transactions, such as prize payments, to promote--
  — (i) innovation in technologies that may assist countermeasure and product advanced research and development;
  — (ii) research on and development of research tools and other devices and technologies; and
  — (iii) research to promote strategic initiatives, such as rapid diagnostics, broad spectrum antimicrobials, and vaccine manufacturing technologies.”

*Pandemic and All-Hazards Preparedness Act, Title IV, Sec. 319L
Call for Innovation to Meet the Challenge of Public Health Emergency Preparedness and Response

• The call for innovation is a recognition that current thinking, approaches, and technologies do not provide adequate solutions to the problem posed

Innovation:

• new idea or method: a new invention or way of doing something

• origination: the act or process of inventing or introducing something new

• What does innovation mean in the context of developing and manufacturing medical countermeasures for public health threats?
Innovations Themes in BARDA Programs

• **New ways to make better countermeasures**
  - Safer
  - More effective
  - More stable
  - More easily manufactured
  - More cost-effective

• **Better ways to make new countermeasures**
  - Faster
  - More reliable and predictable
  - More flexible
  - More expandable (surge capacity)
  - More readily approvable
  - Less costly (capital investment and cost of manufacturing)
### Achieving a More Responsive Capability

#### Current Enterprise vs. “Responsive” Capability

<table>
<thead>
<tr>
<th>Product Development Paradigm</th>
<th>Current Enterprise</th>
<th>“Responsive” Capability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achieving a More Responsive</td>
<td>Driven by commercial markets</td>
<td>Driven by public health</td>
</tr>
<tr>
<td>Capability</td>
<td>Long time-to-market (10-20 yrs)</td>
<td>Able to move quickly from need to solution</td>
</tr>
<tr>
<td></td>
<td>Expensive development (~$1B)</td>
<td>Expedited, affordable</td>
</tr>
<tr>
<td></td>
<td>Favors established techniques</td>
<td>Receptive to new technologies and organizations</td>
</tr>
<tr>
<td></td>
<td>Conducted by large, integrated companies</td>
<td>Versatile, flexible</td>
</tr>
<tr>
<td></td>
<td>One cm/one indication/one approval/one plant regulatory calculus</td>
<td>Able to prepare for potential threats or emerging threats in advance</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Enabling Technologies</th>
<th>Technology and process developed individually with each cm</th>
<th>Broad-spectrum/multi-use products</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fixed manufacturing infrastructure</td>
<td>Platform technologies for development and manufacturing</td>
</tr>
<tr>
<td></td>
<td>Expensive technology and facilities</td>
<td>Template product designs</td>
</tr>
<tr>
<td></td>
<td>Deliberate manufacturing and release technology</td>
<td>Expedited product safety and efficacy testing</td>
</tr>
<tr>
<td></td>
<td>Safety-conscious, individualized regulatory approach</td>
<td>Multi-use facilities</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low-tech/low-cost manufacturing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rapid manufacturing and release</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulatory-friendly approaches</td>
</tr>
</tbody>
</table>
BARDA Programs to Foster Innovation

• Development programs targeting new technologies
  — Request for Proposals
  — Focus on advancement of specific technology identified as key
    (e.g. cell-based and recombinant flu vaccines; flu vaccine adjuvants)

• Call for new technologies in countermeasure development
  — Broad Agency Announcements
  — Open to ideas in general Areas of Interest
    (e.g. CBRN countermeasures; Development/Manufacturing platforms)

• Centers of Innovation for Advanced Development and Manufacturing (ADM)
  — Public-private partnerships
  — Core development/manufacturing services; production surge capacity)

• Strategic Investor
Implementation of BARDA’s Innovation Mandate

• Look to the biopharm/biotetch community to provide fresh ideas for safeguarding public health

• Seek the technological tools to enable a rapidly responsive medical countermeasure capability
  – More effective countermeasures
  – Multi-use products
  – Platform technologies
  – Improved manufacturing infrastructure

• Will provide the flexibility to deal with diverse threats
  – Bioterror
  – Pandemic Influenza
  – Emerging Infectious Diseases
Interfacing with BARDA

• [www.phe.gov](http://www.phe.gov)  
  – Program description, information, news, announcements

• [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov)  
  – Portal to BARDA  
  – Register, request a meeting  
  – Tech Watch

• [www.fedbizopps.gov](http://www.fedbizopps.gov)  
  – Official announcements and detailed information about all government contract solicitations
BARDA: Not Bigger. Smarter!